Login to Your Account

Financings NEWS

LONDON – Quoted technology investor Arix Bioscience plc closed its capital raise at £87 million (US$121 million) after investors took up 14.2 million of the 20 million shares available in the open offer announced on Feb. 28.

PARP 2.0

In the two years since Ideaya Biosciences Inc. closed its $40 million series A, the South San Francisco-based company has grown from two to 42 employees, identified lead programs in synthetic lethality and immunotherapy, prepared to file three INDs in the next 12 to 18 months and positioned itself to move multiple candidates into the clinic by the end of 2019. That trajectory was more than sufficient to attract $94 million in a series B financing that will see the company into the second half of 2021, according to CEO Yujiro S. Hata.

Foghorn Therapeutics Inc., a Cambridge, Mass.-based startup devoted to developing new cancer drugs that exploit the chromatin regulatory system to direct gene expression, has launched with an initial capital commitment of $50 million from Flagship Pioneering, the 17-year-old venture firm previously known as Flagship Ventures.

More Financings Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: